insomnia

Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ®…

6 days ago

Idorsias daridorexant in women during menopausal transition age with insomnia

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared…

3 months ago